Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury

Journal of Clinical Pharmacology

Volumn 40, Issue 4, 2000, Pages 402-409

  Jack L Segal, M D ^a   Hayes, Keith C ^b   Brunnemann, Sherry R ^a   Hsieh, Jane T C ^b   Potter, Patrick J ^b   Pathak, Mayank S ^c   Tierney, David S ^d   Mason, David ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^d Élan Pharmaceutical Research Corporation   (United States)

^e Athena Neurosciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; PLACEBO;

ADRENERGIC SYSTEM; AREA UNDER THE CURVE; ARTICLE; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSAGE FORM; FEMALE; HUMAN; MALE; PARAPLEGIA; QUADRIPLEGIA; RANDOMIZED CONTROLLED TRIAL; SPINAL CORD INJURY; SUSTAINED RELEASE PREPARATION;

4-AMINOPYRIDINE; ABSORPTION; ADULT; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHRONIC DISEASE; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PARAPLEGIA; QUADRIPLEGIA; SEVERITY OF ILLNESS INDEX; SPINAL CORD INJURIES; TIME FACTORS;

EID: 0033635393     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022008982     Document Type: Article

References (44)

1. Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: A long-term, controlled trial
2. 4-Aminopyridine in chronic spinal cord injury: A controlled, double-blind, crossover study in eight patients
3. Preclinical trial of 4-aminopyridine in patients with chronic spinal cord injury
4. 4-Aminopyridine-sensitive neurologic deficits in patients with spinal cord injury
5. 4-Aminopyridine and spinal cord injury: A review
6. Sustained improvements in neurological function in spinal cord injured patients using oral 4-aminopyridine: 3 Cases
7. Randomized double-blind crossover trial of fampridine (4-aminopyridine) in patients with incomplete spinal cord injury
8. A reversed-phase ion-pair liquid chromatography method for the determination of 4-aminopyridine in Sprague-Dawley rats
9. Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury
10. 4-Aminopyridine improves pulmonary function in quadriplegic humans with longstanding spinal cord injury
11. 4-Aminopyridine alters gait characteristics and enhances locomotion in spinal cord injured humans
12. Physiological effects of 4-aminopyridine on demyelinated mammalian motor and sensory fibers
13. Effect of 4-aminopyridine on axonal conduction block in chronic spinal cord injury
14. The effects of 4-aminopyridine and tetraethylammonium ions on normal and demyelinated mammalian nerve fibres
15. Differential effects of low and high concentrations of 4-aminopyridine on axonal conduction in normal and injured spinal cord
16. 4-Aminopyridine leads to restoration of conduction in demyelinated rat sciatic nerve
17. Effects of 4-aminopyridine at the frog neuromuscular junction
18. Aminopyridine and synaptic transmission
19. 4-Aminopyridine in the treatment of patients with multiple sclerosis: Long-term efficacy and safety
20. Characterization of 4-aminopyridine in overdose
21. Quantitative assessment of sustained release 4-aminopyridine for symptomatic treatment of multiple sclerosis
22. Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies
23. The international standards booklet for neurological and functional classification of spinal cord injury
24. Rehabilitation in patients with spinal cord disorders
25. Pharmacokinetic considerations in rational drug design
26. Therapeutic relevance of pharmacokinetics and pharmacodynamics
27. Role of metabolism and pharmacokinetic studies in the discovery of new drugs - Present and future perspectives
28. Gastric emptying is impaired in patients with spinal cord injury
29. Decreased theophylline bioavailability and impaired gastric emptying in spinal cord injury
30. Orally administered 4-aminopyridine improves clinical signs in multiple sclerosis
31. Mechanism of action of 4-aminopyridine in the symptomatic treatment of multiple sclerosis
32. The effect of 4-aminopyridine on the clinical signs in multiple sclerosis: A randomized, placebo-controlled, double-blind, crossover study
33. 4-Aminopyridine induces functional improvement in multiple sclerosis patients: A neurophysiological study
34. 4-Aminopyridine in patients with multiple sclerosis: Dosage and serum level related to efficacy and safety
35. 4-Aminopyridine improves clinical signs in multiple sclerosis
36. 4-Aminopyridine in multiple sclerosis: Prolonged administration
37. The current status of studies of aminopyridines in patients with multiple sclerosis
38. The effects of 4-aminopyridine in multiple sclerosis patients: Results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial
39. Clinical pharmacology of spinal cord injury
40. Pharmacokinetics of 4-aminopyridine in human volunteers: A preliminary study using a new GLC method for its estimation
41. 4-Aminopyridine kinetics
42. 4-Aminopyridine is superior to 3, 4-diaminopyridine in the treatment of patients with multiple sclerosis
43. Poisoning with 4-aminopyridine: Report of three cases
44. Severe poisoning by 4-aminopyridine in a body builder